Jump to content

Singapore may get non-mRNA Novavax Covid-19 vaccine

Kb27

By Kb27,
in Lite & EZ

 Share

Recommended Posts

kobayashiGT

kobayashiGT

Internal Moderator
38 minutes ago, Windwaver said:

You're right on that insufficient time for your body to recover, I'm pretty sure that is the same for many people out there that are still suffering from side effects after months of their vaccine shots.

However, ivory tower is saying we should shorten our shots instead so I guess unless they see larger number of people dropping dead, it's just going to get shorter. Even if people are not dropping dead, it's not exactly useful to our economy if people are sick from chronic side effects from vaccination.

Maybe we should get a medically trained person to be health minister?

Mf2apsg.gif200.gif

Woah. the deep fake is real.

🤣

↡ Advertisement
Link to post
Share on other sites
Sosaria

Sosaria

Twincharged
On 1/13/2022 at 1:51 PM, happy_man said:

Alamak. 2022 liao and still the US-made protein-based vaccine still akan datang ?  WTF ?!😝

50% of our children already mRNA'd liao.

10 Jan 2022 - https://www.cnbc.com/2022/01/10/novavax-ceo-covid-vaccine-could-be-cleared-in-multiple-countries-soon.html

...The company submitted its final data to the U.S. Food and Drug Administration on New Year’s Eve (2021). It has yet to file the full application for emergency-use authorization...

Might be because huge stock of mRNA vaccines on hand or earlier committed to buy so no choice got to use these up before it expires.  

  • Praise 2
Link to post
Share on other sites
Fcw75

Fcw75

Hypersonic
9 hours ago, happy_man said:

Not fake lah...More like trying to convince pple to accept certain vaccines over other...and this had been going on since Jun 2021 😜

Remember just 6 months ago, our esteemed Committee of Experts suggested mRNA Vaccines are "Safe and Effective" while suggesting non mRNA vaccines like Sinovac effectiveness as "unknown" with "51% Efficacy" ?

What happen now ? The same group of "experts" now like flip prata selectively promoting Novavax as "more effective" than other non-mRNA vaccines. What they are NOT saying is why they seems to be looking for another  non mRNA vaccines (as booster shots) when we already have 2 mRNA in over 99% of SGreans bodies?  😜

https://www.moh.gov.sg/news-highlights/details/ec19v-continues-to-endorse-the-effectiveness-of-the-mrna-covid-19-vaccines

Do you know the meaning of Deep Fake? It’s not even what you are talking about.

  • Haha! 2
Link to post
Share on other sites
Windwaver

Windwaver

Turbocharged
On 1/14/2022 at 10:50 AM, inlinesix said:

He has hyperthyroidism.  That's why he is not taking booster for the time being.

I'm pretty sure doctors will say

20402-ben-risk.jpg

:grin:

  • Praise 1
Link to post
Share on other sites
Stary

Stary

Supercharged
On 1/24/2022 at 11:24 PM, 13177 said:

Hopefully sg will approves soon also?! And will allow anyone to take this vaccine as booster?! 😂

Give it to the unvax first so that they can save their livelihoods.

 

  • Praise 1
Link to post
Share on other sites
Ender

Ender

Hypersonic
12 minutes ago, Starry said:

Give it to the unvax first so that they can save their livelihoods.

 

Also to the under 40s for boosting. Needless heart injury when their covid risk is so low. 

Link to post
Share on other sites
Kb27

Kb27

Supersonic
  • Author
(edited)

Corbevax just as powerful as Novavax, should be pursued by HSA

 

CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally

The world now has a new COVID-19 vaccine in its arsenal, and at a fraction of the cost per dose.

Two years into the COVID-19 pandemic, the world has seen over 314 million infections and over 5.5 million deaths worldwide. Approximately 60% of the world population has received at least one dose of a COVID-19 vaccine. But there is still a glaring and alarming gap in global access to these vaccines. As a virologist who has followed this pandemic closely, I contend that this vaccine inequity should be of grave concern to everyone.

If the world has learned anything from this pandemic, it’s that viruses do not need a passport. And yet approximately 77% of people in high- and upper-middle-income countries have received at least one dose of the vaccine – and only 10% in low-income countries. Wealthy countries are giving boosters, and even fourth doses, while first and second doses are not available to many worldwide.

But there is hope that a new vaccine called CORBEVAX will help close this vaccination gap.

How does the CORBEVAX vaccine work?

All COVID-19 vaccines teach the immune system how to recognize the virus and prepare the body to mount an attack. The CORBEVAX vaccine is a protein subunit vaccine. It uses a harmless piece of the spike protein from the coronavirus that causes COVID-19 to stimulate and prepare the immune system for future encounters with the virus.

Unlike the three vaccines approved in the U.S. – Pfizer and Moderna’s mRNA vaccines and Johnson & Johnson’s viral vector vaccine, which provide the body instructions on how to produce the spike protein – CORBEVAX delivers the spike protein to the body directly. Like those other approved COVID-19 mRNA vaccines, CORBEVAX also requires two doses.

How was CORBEVAX developed?

CORBEVAX was developed by the co-directors of the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, Drs. Maria Elena Bottazzi and Peter Hotez.

During the 2003 SARS outbreak, these researchers created a similar type of vaccine by inserting the genetic information for a portion of the SARS virus spike protein into yeast to produce large amounts of the protein. After isolating the virus spike protein from the yeast and adding an adjuvant, which helps trigger an immune response, the vaccine was ready for use.

The first SARS epidemic was short-lived, and there was little need for Bottazzi and Hotez’s vaccine – until the virus that causes COVID-19, SARS-CoV-2, emerged in 2019. So they dusted off their vaccine and updated the spike protein to match that of SARS-CoV-2, creating the CORBEVAX vaccine.

Two large clinical trials of over 3,000 people in India found the vaccine to be safe, well-tolerated and over 90% effective at preventing symptomatic infections from the original strain of COVID-19, and over 80% effective against the delta variant. The vaccine received emergency use authorization in India, and other developing countries are expected to follow.

Interestingly, the group at Baylor was not able to drum up interest or funding in the U.S. for their vaccine. Instead, newer technologies such as mRNA vaccines raced ahead, even though Bottazzi and Hotez’s vaccine design was more advanced, thanks to their previous work during the 2003 SARS and 2012 MERS outbreaks.

A vaccine built for the world

Protein subunit vaccines have an advantage over mRNA vaccines in that they can be readily produced using well-established recombinant DNA technology that is relatively inexpensive and fairly easy to scale up. A similar protein recombinant technology that’s been around for 40 years has been used for the Novavax COVID-19 vaccine, which is available for use in 170 countries, and the recombinant hepatitis B vaccine.

This vaccine can be produced at a much larger scale because appropriate manufacturing facilities are already available. Also key to global access is that CORBEVAX can be stored in a regular refrigerator. Therefore, it is possible to produce millions of doses rapidly and distribute them relatively easily. In comparison, producing mRNA vaccines is more expensive and complicated because they are based on newer technologies, rely on highly skilled workers and often require ultralow temperatures for storage and transport.

Another major difference is that the CORBEVAX vaccine was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine using a well-tested and safe method. Key to this, the researchers were not concerned with intellectual property or financial benefit. The vaccine was produced without significant public funding; the US million needed for development was provided by philanthropists.

COBREVAX is currently licensed patent-free to Biological E. Limited (BioE), India’s largest vaccine maker, which plans to manufacture at least 100 million doses per month starting in February 2022. This patent-free arrangement means that other low- and middle-income countries can produce and distribute this cheap, stable and relatively easy-to-scale vaccine locally.

Combined, this means that CORBEVAX is one of the cheapest vaccines currently available. How well it works against the omicron variant is under investigation. However, the CORBEVAX story can be used as a model to address vaccine inequity when it is necessary to vaccinate the world population – against COVID-19 and other diseases on the horizon.

Edited by Kb27
Link to post
Share on other sites
13177

13177

Hypersonic
1 hour ago, Fcw75 said:

Wonder why HSA take so long. Thought Kenneth mak said soon?

Even they approved also dont know who they will allow to jab? I doubts they will open up to anyone?! 🙄

  • Praise 1
Link to post
Share on other sites
Stary

Stary

Supercharged
56 minutes ago, Ender said:

Also to the under 40s for boosting. Needless heart injury when their covid risk is so low. 

Yeap......priority to these too.

Link to post
Share on other sites
Fcw75

Fcw75

Hypersonic
56 minutes ago, Ender said:

The name of their  expert committee sounds like a ranger group in this forum.

 

Can be TIKO or STINKO. 🤣

↡ Advertisement
Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share
Go to topic listing
×
×
  • Create New...